Biomarker proteomics · longitudinal analysis · targeted LC–MS

Connect tissue discovery to biofluid evidence.

An anonymous demonstration of how discovery signals can be prioritized, verified with a multiplex targeted assay, and evaluated across serial biofluid samples before candidates advance.

Explore candidate profiles Review the workflow

2 matricestissue and serial biofluid evidence

3 layersdiscovery, verification, monitoring

Time-awarecandidate trajectories reviewed

Decision-readytransparent evidence tiers

Anonymousillustrative modified values

Analytical workflow

A biomarker signal must survive more than one dataset.

The analytical question changes at every stage: discovery asks what changed, targeted verification asks whether it can be measured reliably, and longitudinal analysis asks when and where the signal is informative.

01 / DISCOVER

Profile tissue broadly

Review data quality, estimate differential abundance, and identify coordinated biological changes.

02 / PRIORITIZE

Rank candidates

Combine effect consistency, biological relevance, peptide suitability, and missingness.

03 / VERIFY

Build a focused panel

Use multiplex targeted measurements to test selected candidates in tissue and biofluid.

04 / MODEL TIME

Compare trajectories

Evaluate baseline separation, onset, peak response, persistence, recovery, and variability.

05 / DECIDE

Assign evidence tiers

Advance, retain for focused follow-up, or deprioritize each candidate with documented reasons.

Interactive evidence explorer

What does each analysis layer contribute?

Select a layer to see its analytical purpose, principal quality risk, and the decision it can support.

Tissue discovery

Proteome-wide candidate generation

Discovery layer

Analytical purposeFind coordinated changesBroad profiling identifies candidate signals and biological processes associated with the experimental contrast.

Main quality riskUnstable rankingSmall groups, missing values, outliers, and correlated proteins can change the apparent shortlist.

Decision supportedPrioritize candidatesSelect a focused set that is biologically meaningful and analytically measurable.

Interpretation: Discovery creates hypotheses. It does not by itself establish a monitoring biomarker.

Candidate evidence profiles

Select a masked candidate to compare its longitudinal pattern and current evidence tier. Values are illustrative.

Candidate A: Early biofluid change with sustained direction and concordant tissue evidence supports advancement.

Candidate A · serial biofluid profile

Relative signal versus the anonymous baseline

Advance

The displayed trajectory is modified and does not reproduce exact study values or sampling times.

What this demonstrates

Translation requires agreement across context, matrix, and time.

A candidate can be strong in tissue but weak in biofluid—or appear early but vary too much to support monitoring. The final shortlist should preserve those distinctions.

Separate discovery from verification

Do not treat broad-screening significance as independent confirmation.

Evaluate matrix concordance

Assess whether tissue biology translates into a measurable biofluid signal.

Use the full trajectory

Onset, persistence, recovery, and variability can matter more than one peak comparison.

Document why candidates advance

Evidence tiers make prioritization and the next validation study easier to defend.

Demonstration scope

Analytical logic retained. Study identity removed.

This public-facing case is derived from a peer-reviewed biomarker-proteomics workflow. It illustrates the analysis strategy without reproducing the publication or attributing the work to QuantiraOmics.

What remains scientifically representative

Label-free tissue discovery followed by multiplex targeted verification.
Candidate assessment across tissue and serial biofluid measurements.
Comparison of candidate trajectories with conventional measurements.
Evidence-based prioritization for subsequent assay and study validation.

What has been anonymized or modified

Disease, biological system, treatment, organizations, authors, study groups, sample counts, analyte identities, instruments, software, thresholds, sampling schedule, and empirical values are omitted or changed.

What the example does not claim

The displayed trajectories do not reproduce the publication.
The example does not establish clinical qualification or regulatory acceptance of a biomarker.
No client, employer, proprietary, patient, or unpublished information is disclosed.

This anonymous educational demonstration preserves the general analytical problem and workflow while removing identifying and exact empirical details.